|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
5R21CA208736-02
|
$180,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
|
1R01CA227466-01
|
$699,062
|
ZIV, ELAD
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
|
1R01CA227505-01
|
$620,860
|
KIRCHHOFF, TOMAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
|
1R01CA231291-01
|
$533,211
|
WELLSTEIN, ANTON
|
GEORGETOWN UNIVERSITY
|
|
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
|
5R01CA205965-02
|
$640,839
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
|
1R01CA219896-01A1
|
$429,943
|
WARGO, JENNIFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy
|
1R01CA219871-01A1
|
$451,326
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
|
1R01CA231325-01
|
$572,540
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-03
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression
|
5R01CA205975-03
|
$386,619
|
GHAFFARI, SAGHI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
|
1R01CA216101-01A1
|
$670,933
|
SHADEL, GERALD
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
5R01CA216273-02
|
$740,321
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
|
1R01CA231295-01
|
$481,288
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQC2) Localization as a determinant of cancer dormancy
|
5R01CA194596-04
|
$525,066
|
LIN, CHARLES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-09
|
$1,304,869
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
5U54CA163068-07
|
$1,751,252
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
3D Models of Immunotherapy
|
5U01CA214369-02
|
$729,562
|
MOONEY, DAVID
|
HARVARD UNIVERSITY
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-03
|
$44,524
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120 02060
|
$79,723
|
Rothman, Nat
|
DCEG (NCI)
|
|
A comparison of interventions to teach patients skin self-examination
|
5R01CA154908-08
|
$724,343
|
ROBINSON, JUNE
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia
|
2R01CA174844-04
|
$575,010
|
RADER, CHRISTOPH
|
SCRIPPS FLORIDA
|
|
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
|
1R01CA222871-01
|
$373,547
|
FISHER, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
A genomewide discovery of chemoresistance-associated noncoding RNAs in human cancers
|
1R21CA226303-01
|
$176,175
|
HE, TONG-CHUAN
|
UNIVERSITY OF CHICAGO
|
|
A germline variant that predicts and modulates the response of melanoma to immunotherapy
|
5R21CA209309-02
|
$237,724
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-10
|
$247,340
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A high-throughput platform for neo-antigen based cancer immunotherapy
|
1R43CA233120-01
|
$299,917
|
XIAO, JUN
|
IMMUDX, LLC
|
|
A Label-Free, Point-of-Care Platform to Diagnose Acute Promyelocytic Leukemia
|
5R01CA190843-04
|
$311,458
|
SOHN, LYDIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
A Molecular Diagnostic Assay for Accurately Differentiating Melanoma from Benign Lesions
|
1R44CA228897-01
|
$299,244
|
HACHEY, DAVID
|
FRONTIER DIAGNOSTICS, LLC
|
|
A Mouse Model of DNMT3A-Associated Hematologic Malignancy
|
5R01CA183252-05
|
$533,845
|
GOODELL, MARGARET
|
BAYLOR COLLEGE OF MEDICINE
|
|
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA
|
5R01CA200919-03
|
$383,156
|
WAJAPEYEE, NARENDRA
|
YALE UNIVERSITY
|
|
A novel genetic pathway for survival of B-lymphoblastic leukemia-initiating cells
|
1R21CA209298-01A1
|
$218,588
|
LI, SHAOGUANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy
|
1R41CA228622-01
|
$298,305
|
NGUYEN, HIEN-ANH
|
ENZYME BY DESIGN, INC.
|
|
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment
|
5R00CA183914-05
|
$148,607
|
WAN, LIXIN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
A Novel Positron Emission Tomography Strategy for Early Detection and Treatment Monitoring of Graft-versus-host Disease
|
5R01CA201719-03
|
$361,510
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
|
A Paradigm Shift in Chronic Lymphocytic Leukemia: Defining the Role of Hematopoietic Stem Cells in Leukemogenesis
|
1F30CA225070-01A1
|
$38,725
|
HU, EILEEN
|
OHIO STATE UNIVERSITY
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
4R44CA217591-02
|
$1,125,311
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
|
3R44CA221513-02S1
|
$4,319
|
DEVENPORT, MARTIN
|
ONCOIMMUNE, INC.
|
|
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
|
5R44CA221513-02
|
$982,509
|
DEVENPORT, MARTIN
|
ONCOIMMUNE, INC.
|
|
A plasticity and reprogramming paradigm for therapy resistance at the single cell level
|
1U01CA227550-01
|
$598,501
|
RAJ, ARJUN
|
UNIVERSITY OF PENNSYLVANIA
|
|
A rapid spontaneous murine model of CN-AML
|
3R01CA196658-03S1
|
$219,775
|
GRIMES, H
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
A rapid spontaneous murine model of CN-AML
|
5R01CA196658-03
|
$567,086
|
GRIMES, H
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
A real-time, cost-effective, accurate UV measurement and sun protection system to prevent and reduce the incidence of sunburn in high-risk consumers.
|
4R44CA224658-02
|
$686,491
|
MEITL, MATTHEW
|
WEARIFI, INC.
|
|
A role for c-Abl/Arg in melanoma progression
|
3R01CA166499-05S1
|
$51,515
|
PLATTNER, RINA
|
UNIVERSITY OF KENTUCKY
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$305,473
|
Tosato, Giovanna
|
CCR (NCI)
|
|
A Self-Regulation Approach to an Indoor Tanning Intervention for Frequent Users
|
5K07CA175115-05
|
$76,512
|
STAPLETON, JEROD
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
A-to-I microRNA Editing and Melanoma Metastasis
|
1R21CA219958-01A1
|
$208,800
|
BARELI, MENASHE
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196 03152
|
$477,453
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
|
1R01CA229851-01
|
$398,271
|
SULLIVAN, RYAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Aberrant signaling in acute myeloid leukemia
|
3R01CA204396-03S1
|
$231,795
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Aberrant signaling in acute myeloid leukemia
|
5R01CA204396-03
|
$459,674
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|